NCT02201212View on ClinicalTrials.gov

Everolimus for Cancer With TSC1 or TSC2 Mutation

PHASE2CompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

June 30, 2019

Study Completion Date

June 30, 2019

Conditions

TSC1TSC2Tuberous Sclerosis ComplexMTOR

Interventions

DRUG

Everolimus

Trial Locations (2)

10065

Memorial Sloan Kettering Cancer Center, New York

02115

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Novartis Pharmaceuticals

All Listed Sponsors

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER